232 related articles for article (PubMed ID: 16691490)
1. Rescue of folding defects in ABC transporters using pharmacological chaperones.
Loo TW; Bartlett MC; Clarke DM
J Bioenerg Biomembr; 2005 Dec; 37(6):501-7. PubMed ID: 16691490
[TBL] [Abstract][Full Text] [Related]
2. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.
Wang Y; Bartlett MC; Loo TW; Clarke DM
Mol Pharmacol; 2006 Jul; 70(1):297-302. PubMed ID: 16624886
[TBL] [Abstract][Full Text] [Related]
3. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound.
Loo TW; Bartlett MC; Clarke DM
Mol Pharm; 2005; 2(5):407-13. PubMed ID: 16196493
[TBL] [Abstract][Full Text] [Related]
4. Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Sep; 279(37):38395-401. PubMed ID: 15247215
[TBL] [Abstract][Full Text] [Related]
5. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.
Wang Y; Loo TW; Bartlett MC; Clarke DM
Mol Pharmacol; 2007 Mar; 71(3):751-8. PubMed ID: 17132688
[TBL] [Abstract][Full Text] [Related]
6. Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect.
Veit G; Oliver K; Apaja PM; Perdomo D; Bidaud-Meynard A; Lin ST; Guo J; Icyuz M; Sorscher EJ; Hartman JL; Lukacs GL
PLoS Biol; 2016 May; 14(5):e1002462. PubMed ID: 27168400
[TBL] [Abstract][Full Text] [Related]
7. Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2002 Aug; 277(31):27585-8. PubMed ID: 12070134
[TBL] [Abstract][Full Text] [Related]
8. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants.
Loo TW; Bartlett MC; Wang Y; Clarke DM
Biochem J; 2006 May; 395(3):537-42. PubMed ID: 16417523
[TBL] [Abstract][Full Text] [Related]
9. Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(44):32043-52. PubMed ID: 17848563
[TBL] [Abstract][Full Text] [Related]
10. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.
Wang Y; Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(46):33247-33251. PubMed ID: 17911111
[TBL] [Abstract][Full Text] [Related]
11. Diminished self-chaperoning activity of the DeltaF508 mutant of CFTR results in protein misfolding.
Serohijos AW; Hegedus T; Riordan JR; Dokholyan NV
PLoS Comput Biol; 2008 Feb; 4(2):e1000008. PubMed ID: 18463704
[TBL] [Abstract][Full Text] [Related]
12. Chemical conjugation of DeltaF508-CFTR corrector deoxyspergualin to transporter human serum albumin enhances its ability to rescue Cl- channel functions.
Norez C; Pasetto M; Dechecchi MC; Barison E; Anselmi C; Tamanini A; Quiri F; Cattel L; Rizzotti P; Dosio F; Cabrini G; Colombatti M
Am J Physiol Lung Cell Mol Physiol; 2008 Aug; 295(2):L336-47. PubMed ID: 18515409
[TBL] [Abstract][Full Text] [Related]
13. Mutations in intracellular loops 1 and 3 lead to misfolding of human P-glycoprotein (ABCB1) that can be rescued by cyclosporine A, which reduces its association with chaperone Hsp70.
Kapoor K; Bhatnagar J; Chufan EE; Ambudkar SV
J Biol Chem; 2013 Nov; 288(45):32622-32636. PubMed ID: 24064216
[TBL] [Abstract][Full Text] [Related]
14. Conserved allosteric hot spots in the transmembrane domains of cystic fibrosis transmembrane conductance regulator (CFTR) channels and multidrug resistance protein (MRP) pumps.
Wei S; Roessler BC; Chauvet S; Guo J; Hartman JL; Kirk KL
J Biol Chem; 2014 Jul; 289(29):19942-57. PubMed ID: 24876383
[TBL] [Abstract][Full Text] [Related]
15. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
Lukacs GL; Verkman AS
Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis: a brief look at some highlights of a decade of research focused on elucidating and correcting the molecular basis of the disease.
Ko YH; Pedersen PL
J Bioenerg Biomembr; 2001 Dec; 33(6):513-21. PubMed ID: 11804193
[TBL] [Abstract][Full Text] [Related]
17. Defining the blanks--pharmacochaperoning of SLC6 transporters and ABC transporters.
Chiba P; Freissmuth M; Stockner T
Pharmacol Res; 2014 May; 83(100):63-73. PubMed ID: 24316454
[TBL] [Abstract][Full Text] [Related]
18. The most common cystic fibrosis-associated mutation destabilizes the dimeric state of the nucleotide-binding domains of CFTR.
Jih KY; Li M; Hwang TC; Bompadre SG
J Physiol; 2011 Jun; 589(Pt 11):2719-31. PubMed ID: 21486785
[TBL] [Abstract][Full Text] [Related]
19. Development of CFTR Structure.
Patrick AE; Thomas PJ
Front Pharmacol; 2012; 3():162. PubMed ID: 22973227
[TBL] [Abstract][Full Text] [Related]
20. Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein.
Sarankó H; Tordai H; Telbisz Á; Özvegy-Laczka C; Erdős G; Sarkadi B; Hegedűs T
Biochem Biophys Res Commun; 2013 Jul; 437(1):140-5. PubMed ID: 23800412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
